Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Irenic Capital Management, a 2% shareholder in Teleflex (NYSE: TFX), urged the Teleflex board to form a Strategic Review sub-committee with new independent directors, a shareholder representative and exclusion of Dr. Klasko to oversee inbound and outbound strategic processes and report back to shareholders.
Irenic said it disagrees with the board's description of their prior conversation and said it looks forward to working with the board to maximize shareholder value.
Teleflex (NYSE:TFX) reiterated its value-maximizing plan following engagement with activist Irenic on March 19, 2026. The company expects previously announced sale transactions to close in the second half of 2026, yielding approximately $1.8 billion of net proceeds after tax.
Teleflex plans to allocate proceeds to a $1.0 billion share repurchase and $800 million debt paydown, pursue a multi-year restructuring targeting about $50 million annual pre-tax savings by mid-2028, and complete announced divestitures while continuing its CEO search.
Summary not available.
o9 announced that Teleflex (NYSE: TFX) went live globally on o9's platform for integrated Demand Planning and Supply Planning on March 12, 2026.
This deployment connects demand forecasts and supply plans in one environment, improving cross-functional coordination, inventory and capacity visibility, forecast performance, and alignment on trade-offs across regions and functions.
Teleflex (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share. The dividend is payable March 31, 2026 to shareholders of record at the close of business on March 6, 2026.
Shareholders registered by the record date will receive the March 31 payment; more corporate details are available from the company.
Teleflex (NYSE: TFX) reported full-year 2025 continuing operations GAAP revenue of $1,992.7M (+17.2%) and adjusted revenue of $1,983.7M (+16.3%). Adjusted diluted EPS from continuing operations was $6.98.
Management provided 2026 outlook: GAAP revenue growth 14.4%–15.4%, pro forma adjusted constant currency revenue growth 4.5%–5.5%, and adjusted diluted EPS $6.25–$6.55. Company announced strategic divestitures, expected H2 2026 close, estimated $1.8B after-tax proceeds, and an initial restructuring to mitigate $48M–$52M annual stranded costs.
Teleflex (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26, 2026.
Participation requires pre-registration to receive dial-in details; the call will be available via live audio webcast on the company website and an audio replay will be available beginning at 11:00 a.m. Eastern Time on February 26, 2026 (conference ID 69028).
Teleflex (NYSE: TFX) appointed Stuart Randle as Interim President and CEO effective immediately and named Dr. Stephen Klasko chairman of the board while the Board engages Spencer Stuart to search for a permanent CEO.
The company provided preliminary full‑year 2025 revenue expectations of $3.270 billion to $3.278 billion, revised from prior guidance of $3.305 billion to $3.320 billion. The reduction reflects softer end‑of‑year demand for intra‑aortic balloon pumps and catheters in the U.S. and Asia, delays in certain OEM purchase orders, and lower order volumes across some portfolio segments. Final fourth quarter and full‑year 2025 results are expected in late February/early March 2026.
Teleflex Medical OEM (to be carved out from Teleflex, NYSE: TFX) will be acquired by Montagu and Kohlberg for $1.5 billion. The carve-out creates an independent contract developer and manufacturer serving structural heart, neurovascular, electrophysiology and urology, with seven facilities across the U.S., Mexico and Ireland.
Closing is expected in second half of 2026, subject to customary regulatory approvals and closing conditions. Greg Stotts will become CEO and Matt Jennings will assume the role of Chairman on closing.
Teleflex (NYSE: TFX) management will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 10:00 a.m. GMT.
A live audio webcast of the presentation will be available on Teleflex's investor website at teleflex.com.